Docetaxel in the treatment of breast cancer: current experience and future prospects.
about
Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancerPharmacogenetics and oncology treatment for breast cancer.Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.
P2860
Docetaxel in the treatment of breast cancer: current experience and future prospects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Docetaxel in the treatment of breast cancer: current experience and future prospects.
@ast
Docetaxel in the treatment of breast cancer: current experience and future prospects.
@en
type
label
Docetaxel in the treatment of breast cancer: current experience and future prospects.
@ast
Docetaxel in the treatment of breast cancer: current experience and future prospects.
@en
prefLabel
Docetaxel in the treatment of breast cancer: current experience and future prospects.
@ast
Docetaxel in the treatment of breast cancer: current experience and future prospects.
@en
P2860
P356
P1476
Docetaxel in the treatment of breast cancer: current experience and future prospects
@en
P2093
Jean-Marc Nabholtz
P2860
P304
P356
10.1586/14737140.5.4.613
P577
2005-08-01T00:00:00Z